OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Kahlon on the Availability of Generic Eltrombopag for Anemia & Thrombocytopenia

May 29th 2025

Kanwarpal S. Kahlon, MD, discusses the benefits of the availability of generic eltrombopag formulations for aplastic anemia and immune thrombocytopenia.

Dr Ali on the Need to Refine Predictive Strategies for Endocrine Sensitivity in HER2-Low Breast Cancer

May 28th 2025

Azka Ali, MD, discusses the need to refine predictive strategies for endocrine sensitivity in HER2-low metastatic breast cancer.

Dr Merrell on Current Treatment Modalities for Gliomas

May 28th 2025

Ryan T. Merrell, MD, discusses current treatment modalities for gliomas in recognition of Brain Tumor Awareness Month.

Dr Atluri on TKI Selection in Chronic Myeloid Leukemia

May 28th 2025

Himchandana Atluri, MD, details factors to consider ahead of TKI selection in patients with chronic myeloid leukemia.

Dr Tarantino on Directions for Prospective Research in HER2+ Metastatic Breast Cancer

May 27th 2025

Paolo Tarantino, MD, PhD, discusses the need for prospective clinical trials to identify treatments for HER2+ breast cancer following progression on T-DXd.

Dr Bowman on Distinctions Between Disease Characteristics and Treatment Response in ccRCC vs Non-ccRCC

May 27th 2025

I. Alex Bowman, MD, discusses the differences in disease presentation between ccRCC and non-ccRCC, as well as standard treatments for these subtypes.

Dr Randall on Consensus Developed at The Annual Birmingham Orthopedic Oncology Meeting

May 27th 2025

R. Lor Randall, MD, FASCO, discusses key areas of consensus discussed at the Annual Birmingham Orthopedic Oncology Meeting.

Dr Nguyen on the Evolving Landscape of Adjuvant Therapy in Localized ccRCC

May 27th 2025

Charles B. Nguyen, MD, discusses the evolving landscape of adjuvant therapy in localized clear cell renal cell carcinoma.

Dr Haldar on the Future Directions for Evaluating NeoAg-VAX in Colorectal Cancer

May 27th 2025

S. Daniel Haldar, MD, explains the future directions for evaluating NeoAg-VAX in colorectal and pancreatic cancer.

Dr Bhat on Selecting Between Liso-Cel and Pirtobrutinib in Relapsed/Refractory CLL

May 26th 2025

Seema A. Bhat, MD, discusses selecting between liso-cel and pirtobrutinib in relapsed/refractory CLL.

Dr Kahl on Persisting Unmet Needs in the Treatment of Mantle Cell Lymphoma

May 26th 2025

Brad Kahl, MD, discusses the ongoing unmet needs in the treatment of mantle cell lymphoma.

Dr McCann on the Biologic Heterogeneity Within HER2+ Breast Cancer

May 26th 2025

Kelly E. McCann, MD, PhD, discusses the biologic heterogeneity within HER2-positive breast cancer and highlights the clinical implications of HR status in this disease subset.

Dr Bekaii-Saab on the RATIONALE-306 Study of Tislelizumab Plus Chemotherapy in Esophageal Cancer

May 26th 2025

Tanios S. Bekaii-Saab, MD, FACP, discusses the use of tislelizumab plus chemotherapy in unresectable or metastatic ESCC.

Dr Tang on the Implementation of Metastasis-Directed Radiotherapy in Oligometastatic ccRCC

May 23rd 2025

Chad Tang, MD, discusses potential roadblocks for the clinical use of metastasis-directed radiotherapy for patients with oligometastatic ccRCC.

Dr Patel on Ongoing Research With Subcutaneous Bispecific Antibodies in Frontline Follicular Lymphoma

May 23rd 2025

Vivek G. Patel, MD, discusses the potential advantages of subcutaneous bispecific antibodies that are being evaluated in frontline follicular lymphoma.

Dr Ip on the Limitations of Real-World CAR T-Cell Therapy Research in LBCL

May 23rd 2025

Andrew Ip, MD, discusses how the limitations of real-world studies reveal gaps in LBCL research that future CAR T-cell therapy clinical trials may address.

Dr Wang on Key Findings From a Study of the Tumor Microenvironment in ccRCC

May 23rd 2025

Yufei Wang, PhD, discusses how the metastasis of ccRCC could rewire the tumor microenvironment and lead to increased immunosuppression and fibrosis.

Dr Ghia on OS Outcomes With Ibrutinib/Venetoclax in CLL Relative to a Matched Healthy Population

May 23rd 2025

Paolo Ghia, MD, PhD, discusses the rationale for conducting an OS analysis of fixed-duration ibrutinib plus venetoclax in patients with CLL.

Dr Lantsman on Future Directions for Evaluating Dostarlimab/Chemo in Endometrial Cancer

May 23rd 2025

Taliya Lantsman, MD, discusses future research directions for assessing dostarlimab/chemotherapy in endometrial cancer in the real-world setting.

Dr Matrana on the Importance of Combination Therapies in Metastatic RCC

May 23rd 2025

Marc R. Matrana, MD, emphasizes the need for combination therapies for the treatment of patients with advanced or metastatic renal cell carcinoma.